BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15491034)

  • 41. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of twice daily application of 2% dorzolamide on intraocular pressure in normal cats.
    Rainbow ME; Dziezyc J
    Vet Ophthalmol; 2003 Jun; 6(2):147-50. PubMed ID: 12753617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428].
    Zeitz O; Matthiessen ET; Reuss J; Wiermann A; Wagenfeld L; Galambos P; Richard G; Klemm M
    BMC Ophthalmol; 2005 Apr; 5():6. PubMed ID: 15811188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers.
    Gatchev E; Petrov A; Kolev E; Hristova R; Demircheva I; Koytchev R; Richter W; Tegel F; Thyroff-Friesinger U
    Arzneimittelforschung; 2011; 61(5):282-6. PubMed ID: 21755811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit.
    Fanous MM; Challa P; Maren TH
    J Ocul Pharmacol Ther; 1999 Feb; 15(1):51-7. PubMed ID: 10048347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST;
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
    Gudmundsdóttir E; Stefánsson E; Bjarnadóttir G; Sigurjónsdóttir JF; Gudmundsdóttir G; Masson M; Loftsson T
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3552-4. PubMed ID: 11006251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
    Simpson AJ; Gray TB; Ballantyne C
    Aust N Z J Ophthalmol; 1996 Feb; 24(1):39-42. PubMed ID: 8743003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.
    Kimal Arici M; Topalkara A; Güler C
    Int Ophthalmol; 1998; 22(1):37-42. PubMed ID: 10090447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep.
    Vanlandingham BD; Maus TL; Brubaker RF
    Ophthalmology; 1998 Aug; 105(8):1537-40. PubMed ID: 9709770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
    Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB
    Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE; Friren B;
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma.
    Avunduk AM; Sari A; Akyol N; Oztürk O; Kapicioglu Z; Erdöl H; Imamoglu HI
    Ophthalmologica; 2001; 215(5):361-5. PubMed ID: 11528262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension.
    Fuchsjäger-Mayrl G; Georgopoulos M; Hommer A; Weigert G; Pemp B; Vass C; Garhöfer G; Schmetterer L
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1289-96. PubMed ID: 19850848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide.
    Larsson LI; Alm A
    Arch Ophthalmol; 1998 Jan; 116(1):19-24. PubMed ID: 9445204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma.
    Simsek T; Yanik B; Conkbayir I; Zilelioglu O
    J Ocul Pharmacol Ther; 2006 Apr; 22(2):79-85. PubMed ID: 16722793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.